Peregrine Pharmaceutical Will (Hepatitis C Treatment Options) Deliver Hepatitus C Phase I Safety Data
Peregrine Pharmaceutical Will Deliver Hepatitus C Phase I Safety Data
Medical News Today - Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a biopharmaceutical company with a portfolio of innovative, clinical stage product candidates for viral diseases and cancer, today announced that it has completed planned patient enrollment and dosing
Pharmacy Benefit
Managed Healthcare Executive - HEPATITIS B AND C are serious viral diseases that can lead to lifelong infection, cirrhosis, liver cancer, liver failure and death. They often produce chronic, hidden infections. An estimated 1.25 million Americans are infected with hepatitis B, and

<< Home